Manufacturers discontinue trial of bintrafusp alfa for use in lung cancer

The decision to stop research on this bifunctional fusion protein targeting TGFβ and PD-L1 for stage IV non-small cell lung cancer was made based on data review indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.

Source:

Biospace Inc.